Xeris Biopharma Holdings Inc (NASDAQ: XERS)’s stock price has plunge by 6.39%relation to previous closing price of $4.77. Nevertheless, the company has seen a 8.91% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-18 that Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company’s revenue is expected to grow significantly by 2030, the stock price may rise accordingly. Moreover, XP-8121 may serve as a catalyst for higher stock valuation.
Is It Worth Investing in Xeris Biopharma Holdings Inc (NASDAQ: XERS) Right Now?
The 36-month beta value for XERS is at 0.69. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for XERS is 147.58M, and currently, shorts hold a 12.16% of that float. The average trading volume for XERS on July 09, 2025 was 2.25M shares.
XERS’s Market Performance
The stock of Xeris Biopharma Holdings Inc (XERS) has seen a 8.91% increase in the past week, with a 10.81% rise in the past month, and a 15.08% gain in the past quarter. The volatility ratio for the week is 4.03%, and the volatility levels for the past 30 days are at 4.29% for XERS. The simple moving average for the last 20 days is 9.69% for XERS stock, with a simple moving average of 29.52% for the last 200 days.
Analysts’ Opinion of XERS
Many brokerage firms have already submitted their reports for XERS stocks, with Piper Sandler repeating the rating for XERS by listing it as a “Neutral.” The predicted price for XERS in the upcoming period, according to Piper Sandler is $3 based on the research report published on November 11, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see XERS reach a price target of $5. The rating they have provided for XERS stocks is “Outperform” according to the report published on March 28th, 2024.
Craig Hallum gave a rating of “Buy” to XERS, setting the target price at $4.50 in the report published on August 28th of the previous year.
XERS Trading at 8.12% from the 50-Day Moving Average
After a stumble in the market that brought XERS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.39% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XERS starting from McCulloch Kevin, who purchase 25,000 shares at the price of $4.38 back on Jun 13 ’25. After this action, McCulloch Kevin now owns 1,708,585 shares of Xeris Biopharma Holdings Inc, valued at $109,475 using the latest closing price.
Stock Fundamentals for XERS
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.81 for the gross margin
The net margin for Xeris Biopharma Holdings Inc stands at -0.2. The total capital return value is set at -0.1.
Based on Xeris Biopharma Holdings Inc (XERS), the company’s capital structure generated 1.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at -7.65. The interest coverage ratio of the stock is -0.73.
Currently, EBITDA for the company is -11.3 million with net debt to EBITDA at -24.29. When we switch over and look at the enterprise to sales, we see a ratio of 4.62. The receivables turnover for the company is 4.8for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
In conclusion, Xeris Biopharma Holdings Inc (XERS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
